Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 15/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16058727 | 0.89 | PTGS1 (0.41) | MAPT | |
| SCHEMBL14975894 | 0.88 | PORCN (0.40) | DHODHALDH1A1MAPTL3MBTL1 | |
| SCHEMBL16056981 | 0.86 | SLC6A7 (0.41) | DHODHALDH1A1MAPTPPARGPPARA | |
| SCHEMBL16057040 | 0.83 | RAB9A (0.44) | ALDH1A1MAPT | |
| SCHEMBL16057423 | 0.82 | CCNC (0.39) | ALDH1A1SLC22A12 | |
| SCHEMBL16058685 | 0.82 | LMNA (0.39) | ALDH1A1L3MBTL1 | |
| SCHEMBL16056911 | 0.81 | ACACB (0.35) | DHODHALDH1A1L3MBTL1 | |
| SCHEMBL16057661 | 0.81 | SLC2A1 (0.42) | ALDH1A1L3MBTL1PPARGPPARA | |
| SCHEMBL16057029 | 0.80 | KDM5A (0.40) | DHODHMAPTPPARGPPARA | |
| SCHEMBL16057874 | 0.79 | LDHA (0.43) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
| WO-2014144836-A2 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | DHODH 2122/4885DHFR 2304/4885ALKBH5 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.